Similarly, mutations involving BRAF, which are prevalent in malignant melanoma, exert an oncogenic effect by activating the downstream MEK/ERK MAPK pathway, resulting in uncontrolled cellular proliferation. The gene discussed is BRAF; the disease is melanoma.